Add to ORKGCommunity-acquired pneumonia (CAP) exhibits mortality rates, between 20 % and 50 % in severe cases. Biomarkers are useful tools for searching for antibiotic therapy modifications and for CAP diagnosis, prognosis and follow-up treatment. This non-systematic state-of-the-art review presents the biological and clinical features of biomarkers in CAP patients, including procalcitonin, C-reactive protein, copeptin, pro-ANP (atrial natriuretic peptide), adrenomedullin, cortisol and D-dimers
The increase and persistence of inflammation in community-acquired pneumonia (CAP) patients can lead...
Severity assessment is a crucial component in the management of patients with community-acquired pne...
Background/aim: There has been growing interest in the use of serum procalcitonin (PCT) and C-reacti...
Community-acquired pneumonia (CAP) exhibits mortality rates, between 20% and 50% in severe cases. Bi...
Community-acquired pneumonia (CAP) exhibits mortality rates, between 20% and 50% in severe cases. Bi...
Community-acquired pneumonia (CAP) is defined as an infection of the alveolar or gas-exchanging port...
Community-acquired pneumonia (CAP) is defined as an infection of the alveolar or gas-exchanging port...
Community-acquired pneumonia (CAP) is a dangerous disease caused by a spectrum of bacterial and vira...
Community-acquired pneumonia (CAP) is a dangerous disease caused by a spectrum of bacterial and vira...
Background Biomarkers may facilitate clinical decisions in order to guide antimicrobial treatment an...
Background Biomarkers may facilitate clinical decisions in order to guide antimicrobial treatment an...
SummaryRationaleOptimal risk prediction of early clinical deterioration in community-acquired pneumo...
BACKGROUND: Biomarkers have been intensively studied in community-acquired pneumonia (CAP) in recent...
Community-acquired pneumonia (CAP) represents a major life-threatening infection, but disease course...
Pneumonia is the leading infectious cause of mortality worldwide and one of the most common lower re...
The increase and persistence of inflammation in community-acquired pneumonia (CAP) patients can lead...
Severity assessment is a crucial component in the management of patients with community-acquired pne...
Background/aim: There has been growing interest in the use of serum procalcitonin (PCT) and C-reacti...
Community-acquired pneumonia (CAP) exhibits mortality rates, between 20% and 50% in severe cases. Bi...
Community-acquired pneumonia (CAP) exhibits mortality rates, between 20% and 50% in severe cases. Bi...
Community-acquired pneumonia (CAP) is defined as an infection of the alveolar or gas-exchanging port...
Community-acquired pneumonia (CAP) is defined as an infection of the alveolar or gas-exchanging port...
Community-acquired pneumonia (CAP) is a dangerous disease caused by a spectrum of bacterial and vira...
Community-acquired pneumonia (CAP) is a dangerous disease caused by a spectrum of bacterial and vira...
Background Biomarkers may facilitate clinical decisions in order to guide antimicrobial treatment an...
Background Biomarkers may facilitate clinical decisions in order to guide antimicrobial treatment an...
SummaryRationaleOptimal risk prediction of early clinical deterioration in community-acquired pneumo...
BACKGROUND: Biomarkers have been intensively studied in community-acquired pneumonia (CAP) in recent...
Community-acquired pneumonia (CAP) represents a major life-threatening infection, but disease course...
Pneumonia is the leading infectious cause of mortality worldwide and one of the most common lower re...
The increase and persistence of inflammation in community-acquired pneumonia (CAP) patients can lead...
Severity assessment is a crucial component in the management of patients with community-acquired pne...
Background/aim: There has been growing interest in the use of serum procalcitonin (PCT) and C-reacti...